Poolbeg Pharma (POLB) Corporate presentation summary

Strategic focus and investment case

• Developing POLB 001 for cancer immunotherapy-induced CRS and an oral GLP-1 obesity treatment, both targeting large unmet needs in growing markets.

• Experienced leadership with a track record of successful transactions and exits.

• Financial runway extends into 2027, supporting near-term clinical milestones and value inflection points.

• Strong emphasis on partnering, with ongoing discussions with major and mid-sized pharma.

POLB 001 clinical and market opportunity

• POLB 001 is a p38 MAPK inhibitor with potential as the first approved preventative therapy for cancer immunotherapy-induced CRS.

• FDA Orphan Drug Designation granted for prevention of T-cell engager bispecific antibody-induced CRS.

• Multi-billion-dollar peak sales potential, with >$10B market opportunity validated by independent research and payer studies.

• Positive preclinical and clinical data show potent inhibition of key inflammatory markers and favorable safety profile.

• Major patent grants and regulatory approvals secured, with exclusivity potentially extending to 2044.

Clinical development and partnerships

• TOPICAL trial in multiple myeloma patients underway, teclistamab supplied by J&J, interim data expected summer 2026.

• RISE programme with University of Manchester and The Christie, supported by a £3.4M MRC grant, further validates CRS research.

• Increased engagement with partners as clinical data approaches, aiming for rapid and compelling proof-of-concept.

• Constructive discussions ongoing with pharma, leveraging high-quality human data and strong IP.